HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

L’Oréal hair color spokesmodel

This article was originally published in The Rose Sheet

Executive Summary

Actress Jessica Biel has signed with L'Oréal to promote Open hair color in an ad campaign breaking in January, the firm says. Open soft-permanent hair color launched last year targeting young women seeking natural-looking hair color (11"The Rose Sheet" April 30, 2001, Marketing In Brief). Biel stars in the TV show "7th Heaven" and in the movie "Summer Catch." Actress also will appear in "The Rules of Attraction," debuting in spring 2002, L'Oréal says. Biel joins L'Oréal's other spokesmodels such as singer Beyonce Knowles of Destiny's Child and actresses Heather Locklear and Claire Forlani...

You may also be interested in...



L'Oreal

Open "soft permanent" hair color will be targeted to young women new to hair coloring and looking for natural-looking color, L'Oreal says. Launching this summer in 24 shades with names like Venus, Orion and Zenith, Open will have different target audience than L'Oreal's Feria, which attracts young, hip fashion crowd. Retailing for $9.99, Open will join growing number of brands aiming to attract consumers seeking natural-looking hair color. L'Oreal is launching Garnier Lumia hair color in June, and Clairol's Herbal Essences hair color will debut in May (1"The Rose Sheet" April 9, p. 10 and 2March 19, p. 5)

Chinese Firms Up Their Game In Novel Flu Antiviral Development

Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.

Quotable: Words Of Wisdom From Our Recent APAC Coverage

Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.

Latest Headlines
See All
UsernamePublicRestriction

Register

RS009925

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel